ANL 32.21 Increased By ▲ 0.51 (1.61%)
ASC 18.65 Increased By ▲ 1.20 (6.88%)
ASL 26.45 Decreased By ▼ -0.15 (-0.56%)
AVN 91.35 Increased By ▲ 0.85 (0.94%)
BOP 8.21 Increased By ▲ 0.03 (0.37%)
BYCO 11.84 Increased By ▲ 0.49 (4.32%)
DGKC 126.00 Decreased By ▼ -2.50 (-1.95%)
EPCL 48.20 Increased By ▲ 0.05 (0.1%)
FCCL 23.96 Increased By ▲ 0.06 (0.25%)
FFBL 27.90 Decreased By ▼ -0.09 (-0.32%)
FFL 17.79 Decreased By ▼ -0.15 (-0.84%)
HASCOL 11.45 Increased By ▲ 0.25 (2.23%)
HUBC 78.30 Decreased By ▼ -0.70 (-0.89%)
HUMNL 8.64 Decreased By ▼ -0.08 (-0.92%)
JSCL 24.65 Increased By ▲ 0.35 (1.44%)
KAPCO 44.75 Increased By ▲ 0.06 (0.13%)
KEL 4.19 Decreased By ▼ -0.03 (-0.71%)
LOTCHEM 16.31 Decreased By ▼ -0.29 (-1.75%)
MLCF 46.70 Decreased By ▼ -0.35 (-0.74%)
PAEL 36.20 Increased By ▲ 0.32 (0.89%)
PIBTL 11.04 Decreased By ▼ -0.11 (-0.99%)
POWER 10.08 Decreased By ▼ -0.02 (-0.2%)
PPL 90.20 Decreased By ▼ -0.50 (-0.55%)
PRL 26.25 Increased By ▲ 0.31 (1.2%)
PTC 14.00 Increased By ▲ 0.99 (7.61%)
SILK 1.58 Increased By ▲ 0.02 (1.28%)
SNGP 48.20 Increased By ▲ 0.25 (0.52%)
TRG 168.50 Decreased By ▼ -3.30 (-1.92%)
UNITY 49.39 Increased By ▲ 0.14 (0.28%)
WTL 4.26 Increased By ▲ 0.01 (0.24%)
BR100 5,282 Increased By ▲ 24.37 (0.46%)
BR30 27,601 Increased By ▲ 45.56 (0.17%)
KSE100 48,305 Increased By ▲ 53.23 (0.11%)
KSE30 19,479 Decreased By ▼ -58.87 (-0.3%)
World

Aspirin does not improve survival in COVID-19 patients: UK study

  • The scientists behind the trial, which is looking into a range of potential treatments for COVID-19, evaluated aspirin's effects on nearly 15,000 hospitalised patients infected with the novel coronavirus.
  • In the study, named RECOVERY, a little less than half of the patients were selected at random and given 150mg of aspirin once a day, and the remaining were given usual care alone.
08 Jun 2021

Aspirin does not improve the chances of survival in severely ill COVID-19 patients, early results from one of Britain's biggest trials studying the commonly used painkiller and blood thinner showed on Tuesday.

The scientists behind the trial, which is looking into a range of potential treatments for COVID-19, evaluated aspirin's effects on nearly 15,000 hospitalised patients infected with the novel coronavirus.

Since the drug helps reduce blood clots in other diseases, it was tested in COVID-19 patients who are at a higher risk of clotting issues.

"Although aspirin was associated with a small increase in the likelihood of being discharged alive, this does not seem to be sufficient to justify its widespread use for patients hospitalised with COVID-19," said Peter Horby, co-chief investigator of the trial.

In the study, named RECOVERY, a little less than half of the patients were selected at random and given 150mg of aspirin once a day, and the remaining were given usual care alone.

The trial, run by the University of Oxford, is also looking at the effectiveness of several other treatments, and was the first to show that the widely available steroid dexamethasone, could save lives of people severely ill with COVID-19.

The aspirin study did not show any significant change to the risk of patients progressing to invasive mechanical ventilation. For every 1,000 patients treated with the medicine, about six more patients experienced a major bleeding event and about six fewer experienced a clotting event, Oxford said.

Oxford said the results would be published on online portal medRxiv, and have been submitted for publication at a peer-reviewed medical journal.

RECOVERY also showed anti-inflammatory treatment tocilizumab significantly reduced deaths, but found no benefit for COVID-19 patients from drugs such as antibiotic azithromycin and anti-malarial drug hydroxychloroquine.